NCT00803933View on ClinicalTrials.gov

Trial of DB289 for the Treatment of Stage I African Trypanosomiasis

PHASE2CompletedINTERVENTIONAL
Enrollment

111

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

February 29, 2004

Study Completion Date

June 30, 2005

Conditions
African Trypanosomiasis
Interventions
DRUG

DB289

Pafuramidine maleate (DB289), 100 mg BID orally

DRUG

Pentamidine

Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM

Trial Locations (2)

Unknown

CDTC Maluku, Gombé

Vanga Hospital, Gombé

Sponsors
All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Immtech Pharmaceuticals, Inc

INDUSTRY